Ireland
--:--IST
Latest
Clinical Trials in France / NCT05783466
Recruiting Not applicable

Dairy Lipids and Cardiometabolic Risk

NCT05783466 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-06-28
Last updated
2025-06-18

Condition(s) studied

Morbid Obesity

Investigational drug(s) / intervention(s)

Low-fat dairy productsWhole-fat dairy productsMilk polar lipid enriched whole-fat dairy products

Low-fat dairy products: 3-month intervention

Whole-fat dairy products: 3-month intervention

Milk polar lipid enriched whole-fat dairy products: 3-month intervention

Study summary

It is a randomized parallel arm intervention study in adults with severe obesity. The objective is to demonstrate that within a dietary handling for weight loss, the daily ingestion during 3 months of whole dairy products enriched with milk polar lipids or whole dairy products decreases to a greater extent fasting plasma apolipoprotein B concentrations than the daily ingestion of low-fat dairy products (control group).

Metabolic parameters will be assessed before and after the 3-month intervention, both at fasting and in postprandial period after the consumption of standardized meals.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Men and women between 18-70 years * Body Mass Index (BMI) between 35 and 60 kg/m2 inclusive * Stable body weight (weight change +/- 5 % for 3 months prior to screening) * Consumption of at least 1 serving/day of dairy products made from cow's milk * Informed consent Exclusion Criteria: * History of bariatric or digestive surgery or disease interfering with main outcomes * Drinking more than 3 glasses of alcohol per day (\>30g/day) * Pregnancy, parturiency or breastfeeding * Food allergies or intolerance to dairy products * Dietary restriction (vegetarian or lactovegetarian) or high protein diet * Use of dietary supplements * Treated with lipid lowering drugs (fibrates, statins, anti-PCSK9, ezetimibe, cholestyramine) within the last 6 weeks before study entry * Treated with insulin, GLP-1 analogs, acarbose, corticoids, beta-blockers. * Medications interfering with intestinal microbiota (beta-lactamines within 3 months before the study or laxatives) * Smoking ≥ 5 cigarettes/day during the past 6 months.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Centre de Recherche en Nutrition Humaine Rhône-Alpes Pierre-Bénite France Active Not Recruiting
Centres Hospitalier Lyon Sud, Service d'Endocrinologie-Diabète-Nutrition Pierre-Bénite France Recruiting

More Hospices Civils de Lyon trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05783466 on ClinicalTrials.gov ↗ ← All trials in France